Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Third Phase III Success Puts Lexicon/Sanofi's Sotagliflozin On Track For NDA Filing

Executive Summary

Intended mainly to provide evidence of a safety advantage compared to existing SGLT2 inhibitors, meeting the net-benefit primary endpoint in the inTandem3 trial puts sotagliflozin in good shape for approval as add-on glycemic-control therapy in type 1 diabetes.

Advertisement

Related Content

Keeping Track: Submissions Galore, Blincyto Supplemental Approval, And Priority Review For Opdivo/Yervoy Combo
Finance Watch: The Year's Biggest IPO And A Post-ASH Offering Splash
No Break For Sanofi: Seals Another Diabetes Deal
Lexicon Share Spike On Carcinoid Syndrome Phase III Data

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC098916

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel